Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 30, 2020

View Archived Issues

Snake venom organoid gives toxin insights

Dosing initiated in first-in-human study of IK-175

Novel cynomolgus macaque model for Sudan virus disease

FDA approves Monoferric injection for the treatment of iron deficiency anemia

Erleada receives extended approval in Europe for metastatic hormone-sensitive prostate cancer

AgeX Therapeutics collaborates with Japanese biopharma to generate hypoimmunogenic cells

Spring Bank discontinues development of inarigivir and all HBV programs

Positive preliminary data from first patient in diverticulosis pilot trial of PGLG

Unum provides update on phase I study of ACTR-707 plus trastuzumab

H84T engineered banana lectin shows efficacy in influenza virus infection models

Pfizer presents phase I data for PF-04518600 in HCC

Phase II data presented for BPM-31510 plus gemcitabine in advanced PDAC

Novel coronavirus emerges rapidly; so does science

Guangzhou Wellhealth Bio-Pharmaceutical discloses new PD-1/PD-L1 inhibitors

Adenosine A2A/A2B antagonists patented by Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical

Abbisko Therapeutics identifies PD-1/PD-L1 interaction inhibitors

New PD-1/PD-L1 interaction inhibitors presented by Betta Pharmaceuticals

CNRS and collaborators patent compounds for RNA virus infections

MicroCures advances burn wound healing collaborative research project

NIH grant supports Gladstone's investigation of how apoE4 causes neurodegeneration in Alzheimer's

EMD Serono studies M-1774 in first-in-human study for solid tumors

Cynomolgus macaque Marburg virus model developed using aerosol exposure

New phase II trial studies REGN-4461 for generalized lipodystrophy

Sanofi reports topline results with olipudase alfa in acid sphingomyelinase deficiency

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...